Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	1 Months Ended	11 Months Ended	12 Months Ended
	Jan. 29, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Operating expenses:
Research and development	$ 662	$ 95,660	$ 9,301	$ 4,263
General and administrative	121	42,888	1,139	790
Change in fair value of contingent value rights	0	15,082	0	0
Acquired in-process research and development	0	220,454	0	0
Loss from operations	(783)	(374,084)	(10,440)	(5,053)
Interest (expense) income, net	(9)	(1,172)	(68)	5
Amortization of debt discount	(37)	0	(310)	(118)
Debt issuance costs	0	(1,331)	0	0
Other (expense) income, net	0	(4,370)	155	105
Loss before income taxes	(829)	(380,957)	(10,663)	(5,061)
Income tax expense	0	114	0	0
Net loss	(829)	(381,071)	(10,663)	(5,061)
Other comprehensive income (loss):
Foreign currency translation adjustment	107	778	(240)	412
Total comprehensive loss	$ (722)	$ (380,293)	$ (10,903)	$ (4,649)
Net loss per ordinary share - basic (in dollars per share)		$ (5.07)
Net loss per ordinary share - diluted (in dollars per share)		$ (5.07)
Weighted average ordinary shares outstanding - basic (in shares)		75,166,456
Weighted average ordinary shares outstanding - diluted (in shares)		75,166,456